NCT05342428View on ClinicalTrials.gov

Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

August 30, 2023

Study Completion Date

August 30, 2023

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

TLL018 tablets

Oral tablets administered at different doses BID daily for 12 weeks.

Trial Locations (1)

310009

88 Jiefang Road, Shangcheng District, Hangzhou City, Zhejiang Province, Hangzhou

Sponsors
All Listed Sponsors
lead

Hangzhou Highlightll Pharmaceutical Co., Ltd

INDUSTRY